Recently, the Category 1 innovative drug Oteseconazole Capsules of eVENUS PHARMACEUTICAL LABORATORIES INC. is approved by China NMPA. It is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Oteseconazole, as an antifungal drug, is an azole metalloenzyme inhibitor that targets fungal sterol 14α demethylase (CYP51). The marketing of this drug provides new treatment options for patients with severe VVC.
